Drug Approval | April 09, 2025
Shilpa’s Unit-2 passes second consecutive FDA inspection with no 483s
Raichur site is the group’s largest API facility and part of a wider network of seven sites
Raichur site is the group’s largest API facility and part of a wider network of seven sites
Nadda noted that on the basis of economic caste census, 50 crore people were brought under this scheme
Sumitomo Chemical began its nucleic acid drug substance contract manufacturing business in 2013
The portfolio includes branded injectable cephalosporines for infectious diseases
The company expects to launch this product through its marketing partner in the near future
New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle AD study
Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone
Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease
Being a premium partner for pharmaceutical companies by contributing to safety and productivity of pharmaceutical manufacture
Subscribe To Our Newsletter & Stay Updated
